Company intelligence / Profile preview
Adrenomed AG
Hennigsdorf, Brandenburg, Germanyadrenomed.com ↗
- Ownership
- Private
- Employees
- ~26
- Development stage
- Other
01
Overview
Adrenomed has developed a first-in-class monoclonal antibody, enibarcimab (formerly adrecizumab), targeting the vasoprotective hormone adrenomedullin. In the Phase II proof-of-concept trial (AdrenOSS‑2) involving patients with septic shock and elevated ADM levels, treatment led to improved organ function and a substantial reduction in short-term mortality (>60% relative reduction at Day 28 in biomarker-defined subgroups). The drug was well tolerated. Enibarcimab received FDA Fast Track designation in April 2024. A confirmatory Phase IIb/III trial is being prepared.
- Therapeutic areas
- OtherInfectious Diseases
- Modalities
- Monoclonal antibodies (mAbs)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Wellington PartnersHBM Healthcare Investments are major investors but not commercial partners; no major pharma partnerships disclosed.
Beyond the preview
Go deeper on Adrenomed AG.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Adrenomed AG.